In our study, 50 bioactive compounds docked against the four targets Human Dipeptidyl Peptidase (DPPIV), Sodium-Glucose Cotransporter-2 (SGLT-2) for diabetes, Human Angiotensin-Converting Enzyme (HACE) for hypertension, and Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) for atherosclerosis. This evidence concerns the gene PCSK9 and atherosclerosis.